Skip to Content

Unlocking the Promise of Biosimilars in Pharmacy Benefit Management

Sep 16, 2022
1:00 pm EDT
Presented by Sandoz
Register Now Registration takes place at a third-party website.

About This Webinar

To date, most FDA-approved biosimilars in the US that are available to patients are primarily administered in a hospital or physician clinic and billed under the medical benefit. But in 2021, we saw the first interchangeable biosimilar insulin approved for patient self-administration, making way for the next wave of pharmacy benefit biosimilars, especially in newer disease areas such as immunology. Self-administered products are primarily billed under the pharmacy benefit, giving PBMs and payers more power to choose what medicines are included on formularies. These medicines will also have a significant impact for patients with inflammatory diseases by providing greater access to treatment options at the pharmacy.

The panel will discuss how the introduction of self-administered biosimilars can impact the inflammatory disease space by providing patients more-affordable, quality treatment options. Speakers will also provide a regulatory background on biosimilar and interchangeable products, discuss how biosimilars promote competition and health system savings and talk about the benefits they can bring to patients and health insurance providers by lowering costs. Speakers will also walk through actionable steps payers can take to promote greater adoption of these biosimilars by ensuring their coverage on formularies.

Attendees Will Learn About

  • Updates from the FDA on biosimilar and interchangeable products
  • Interchangeability and substitution
  • Provider experience with biosimilars
  • The current and future state of biosimilar adoption and coverage in the US


Craig Burton

Senior VP, Policy & Strategic Alliances

Association for Accessible Medicines

Craig Burton is the Senior Vice President of Policy and Strategic Alliances for the Association for Accessible Medicines and the Executive Director of the Biosimilars Council. In his current role, Craig is responsible for leading policy development and issues management for AAM, directing the Biosimilars Council, and building relationships with strategic partners in the health care sector,…

Learn more about Craig Burton

Sarah Ikenberry

Senior Communications Advisor

Food and Drug Administration, Center for Evaluation and Research

Sarah Ikenberry is a Senior Communication Advisor for the Office of Therapeutic Biologics and Biosimilars (OTBB) in the Food and Drug Administration’s (FDA) Center for Evaluation and Research (CDER) where she provides communication advice and support to senior leaders and the agency about communicating strategic priorities, initiatives, and information about biosimilar and interchangeable…

Learn more about Sarah Ikenberry

Colin C. Edgerton, MD, FACP, FACR

Executive Chairman

American Rheumatology Network

Dr. Edgerton is a practicing rheumatologist and the Executive Chairman of the American Rheumatology Network, a physician owned and led organization committed to improving healthcare by empowering independent rheumatology practices across the nation. He is also a founding member of Articularis Healthcare, the largest Rheumatology practice in the United States, spanning 8 states and growing. He…

Learn more about Colin C. Edgerton, MD, FACP, FACR

Ryan Haumschild PharmD, MS, MBA

Director of Pharmacy Services

Emory Healthcare and Winship Cancer Institute

Ryan Haumschild PharmD, MS, MBA is an experienced director of pharmacy at Emory Healthcare and Winship Cancer Institute overseeing profit & loss responsibility, pharmacy operations, clinical services, formulary management, payer and health plan contracting, and medication use across one of the nation’s largest academic integrated delivery networks and Georgia’s only NCI-Designated…

Learn more about Ryan Haumschild PharmD, MS, MBA